|1.||Lothstein, Leonard: 3 articles (10/2010 - 08/2007)|
|2.||Hofmann, Polly A: 2 articles (10/2010 - 11/2007)|
|3.||Sweatman, Trevor W: 2 articles (11/2007 - 08/2007)|
|4.||Rathore, Kusum: 1 article (01/2015)|
|5.||Smolensky, Dmitriy: 1 article (01/2015)|
|6.||Cekanova, Maria: 1 article (01/2015)|
|7.||Grewal, Sukhdeep: 1 article (01/2013)|
|8.||Liu, Yan: 1 article (01/2013)|
|9.||Edwards, Shanique K E: 1 article (01/2013)|
|10.||Covey, Lori R: 1 article (01/2013)|
|2.||Melanoma (Melanoma, Malignant)
01/01/2013 - "Our findings uncovered a novel, PKCδ-independent mechanism of the anti-tumor effects of AD 198, and suggest that AD 198 has therapeutic potential for the treatment of NHL and MM involving TRAF3 inactivation or c-Myc up-regulation."
01/01/2013 - "Detailed mechanistic investigation revealed that AD 198 did not affect PKCδ nuclear translocation, but strikingly suppressed c-Myc expression and inhibited the phosphorylation of ERK, p38 and JNK in TRAF3-/- tumor B cells. "
01/01/2013 - "We found that AD 198 exhibited potent in vitro and in vivo anti-tumor activity on TRAF3-/- tumor B cells, while PEP005 displayed contradictory anti- or pro-tumor activities on different cell lines. "
01/01/1999 - "N-Benzyladriamycin-14-valerate (AD 198) is a semisynthetic anthracycline analogue superior to doxorubicin (DOX) both in vitro and in experimental rodent tumor models, and with differing mechanistic properties from those of the parental antibiotic agent. "
01/01/1989 - "N-Benzyladriamycin-14-valerate (AD 198) is a new lipophilic adriamycin (ADR) analogue that shows marked therapeutic superiority to ADR in murine tumor model systems yet differs mechanistically from ADR in a number of ways. "
01/01/2015 - "N-benzyladriamycin-14-valerate (AD198), a novel derivative of Dox, has a potential to become a more effective treatment than Dox by overcoming drug resistance and cardio-toxicity as shown in the rodent model of lymphoma in vivo. "
01/01/2013 - "In vivo therapeutic effects of AD 198 were assessed using NOD SCID mice transplanted with TRAF3-/- mouse B lymphoma cells. "
01/01/2013 - "N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma."
01/01/2013 - "The present study aimed to evaluate the therapeutic potential of two PKCδ activators, N-Benzyladriamycin-14-valerate (AD 198) and ingenol-3-angelate (PEP005), on NHL and MM. In vitro anti-tumor activities of AD 198 and PEP005 were determined using TRAF3-/- mouse B lymphoma and human patient-derived MM cell lines as model systems. "
|1.||N-benzyladriamycin-14-valerate (AD 198)
|2.||TNF Receptor-Associated Factor 3